Media stories about DarioHealth Corp. (NASDAQ:DRIO) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DarioHealth Corp. earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.097724748807 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- DarioHealth (DRIO) Raises $4.28M Through Private Placement Offerings of Common Stock and Series B Convertible Preferred Stock (streetinsider.com)
- DarioHealth Raises $4.28 Million Through Private Placement Offerings (finance.yahoo.com)
- DarioHealth’s (DRIO) CEO Erez Raphael on Q2 2017 Results – Earnings Call Transcript (seekingalpha.com)
- DarioHealth Reports Second Quarter 2017 Results (finance.yahoo.com)
- DarioHealth Corp. (NASDAQ:DRIO) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS (americanbankingnews.com)
DarioHealth Corp. (NASDAQ DRIO) traded down 11.90% on Friday, reaching $2.00. The company’s stock had a trading volume of 109,778 shares. The firm’s 50-day moving average price is $2.49 and its 200 day moving average price is $2.99. DarioHealth Corp. has a 52-week low of $1.81 and a 52-week high of $4.70. The company’s market cap is $19.04 million.
DarioHealth Corp. (NASDAQ:DRIO) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.13. DarioHealth Corp. had a negative return on equity of 626.32% and a negative net margin of 206.95%. The firm had revenue of $1.21 million during the quarter. Equities analysts anticipate that DarioHealth Corp. will post ($0.41) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact DarioHealth Corp. (DRIO) Share Price” was published by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://rinconhillneighbors.org/2017/08/19/dariohealth-corp-drio-earning-somewhat-positive-news-coverage-accern-reports-updated.html.
About DarioHealth Corp.
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.
Receive News & Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related companies with our FREE daily email newsletter.